Literature DB >> 19787702

Androgen receptor and caveolin-1 in prostate cancer.

Nigel Bennett1, John D Hooper, C Soon Lee, Glenda C Gobe.   

Abstract

The androgen receptor (AR) is involved in the development and maintenance of the normal prostate and the development and progression of prostate cancer (PCa). Caveolin-1 (cav-1) is an AR co-regulator. The expression of this integral membrane protein is upregulated in PCa and correlates positively with its development. This review focuses on the likely interactive roles of AR and cav-1, with particular reference to progression to androgen-insensitivity in PCa. The classical role of AR is modulation of gene transcription by binding specific DNA sequences called androgen response elements in the promoter regions of target genes. To carry out this role, AR interacts with many co-regulator proteins which either enhance or repress its activation. Altered expression or misregulated activation of a co-regulator protein may significantly alter AR activity and the basal transcription rate of androgen responsive genes. Cav-1 has roles in cell signalling and trafficking, roles that are important in PCa survival, metastasis, and the development of multidrug resistant phenotypes. Although cav-1 appears to increase AR genomic activity and increase tumor cell survival, there is also mounting evidence that cav-1 can manipulate rapid, non-genomic AR signalling at the plasma membrane. By increasing our understanding of cav-1 as an AR co-regulator, we may be able to reinstate appropriate transcriptional responses to androgen signalling and minimise misregulated AR activity, thus permitting more effective targeted therapies for PCa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787702     DOI: 10.1002/iub.244

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  10 in total

1.  Expression of PTRF in PC-3 Cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways.

Authors:  Kerry L Inder; Yu Zi Zheng; Melissa J Davis; Hyeongsun Moon; Dorothy Loo; Hien Nguyen; Judith A Clements; Robert G Parton; Leonard J Foster; Michelle M Hill
Journal:  Mol Cell Proteomics       Date:  2011-10-26       Impact factor: 5.911

Review 2.  Understanding extranuclear (nongenomic) androgen signaling: what a frog oocyte can tell us about human biology.

Authors:  Aritro Sen; Hen Prizant; Stephen R Hammes
Journal:  Steroids       Date:  2011-02-25       Impact factor: 2.668

3.  ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.

Authors:  Daria Fleyshman; Peter Cheney; Anda Ströse; Shaila Mudambi; Alfiya Safina; Mairead Commane; Andrei Purmal; Kelsey Morgan; Nicholas J Wang; Joe Gray; Paul T Spellman; Natalia Issaeva; Katerina Gurova
Journal:  Cell Cycle       Date:  2015-12-22       Impact factor: 4.534

4.  Gene expression profiling analysis of castration-resistant prostate cancer.

Authors:  Xuelei Wang; Jiling Wen; Rongbing Li; Guangming Qiu; Lan Zhou; Xiaofei Wen
Journal:  Med Sci Monit       Date:  2015-01-16

Review 5.  Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer.

Authors:  Isabel Ben-Batalla; María Elena Vargas-Delgado; Gunhild von Amsberg; Melanie Janning; Sonja Loges
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

6.  mGluR5 Mediates Dihydrotestosterone-Induced Nucleus Accumbens Structural Plasticity, but Not Conditioned Reward.

Authors:  Kellie S Gross; Kelsey M Moore; Robert L Meisel; Paul G Mermelstein
Journal:  Front Neurosci       Date:  2018-11-20       Impact factor: 4.677

7.  Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

Authors:  Nelson T Gross; Jianmin Wang; Michael V Fiandalo; Eduardo Cortes Gomez; Anica Watts; Alejandro S Godoy; Gary J Smith; Yue Wu
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

8.  Small-molecule hormones: molecular mechanisms of action.

Authors:  Monika Puzianowska-Kuznicka; Eliza Pawlik-Pachucka; Magdalena Owczarz; Monika Budzińska; Jacek Polosak
Journal:  Int J Endocrinol       Date:  2013-02-28       Impact factor: 3.257

9.  Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells.

Authors:  Agnieszka Wanda Piastowska-Ciesielska; Marcin Kozłowski; Waldemar Wagner; Kamila Domińska; Tomasz Ochędalski
Journal:  Arch Med Sci       Date:  2012-10-08       Impact factor: 3.318

10.  Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.

Authors:  Neill Patani; Anita K Dunbier; Helen Anderson; Zara Ghazoui; Ricardo Ribas; Elizabeth Anderson; Qiong Gao; Roger A'hern; Alan Mackay; Justin Lindemann; Robert Wellings; Jill Walker; Irene Kuter; Lesley-Ann Martin; Mitch Dowsett
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.